Calcium signaling dysfunction in schizophrenia: a unifying approach

The present paper demonstrates a remarkable pervasiveness of underlying Ca(2+) signaling motifs among the available biochemical findings in schizophrenic patients and among the major molecular hypotheses of this disease. In addition, the paper reviews the findings suggesting that Ca(2+) is capable of inducing structural and cognitive deficits seen in schizophrenia. The evidence of the ability of antipsychotic drugs to affect Ca(2+) signaling is also presented. Based on these data, it is proposed that altered Ca(2+) signaling may constitute the central unifying molecular pathology in schizophrenia. According to this hypothesis schizophrenia can result from alterations in multiple proteins and other molecules as long as these alterations lead to abnormalities in certain key aspects of intracellular Ca(2+) signaling cascades.

[1]  D. Weinberger,et al.  Dopamine, the prefrontal cortex and schizophrenia , 1997, Journal of psychopharmacology.

[2]  C. Cepeda,et al.  Dopamine and N-Methyl-D- Aspartate Receptor Interactions in the Neostriatum , 1998, Developmental Neuroscience.

[3]  J. Smythies Oxidative reactions and schizophrenia: A review-discussion , 1997, Schizophrenia Research.

[4]  J. Trojanowski,et al.  Gene expression profile for schizophrenia: discrete neuron transcription patterns in the entorhinal cortex. , 2002, Archives of general psychiatry.

[5]  P. Hof,et al.  targeted disruption of the dopamine D2 and D3 receptor genes leads to different alterations in the expression of striatal Calbindin-D28k , 2000, Neuroscience.

[6]  A. Baines,et al.  Ca2+-dependent interaction with calmodulin is conserved in the synapsin family: identification of a high-affinity site. , 1997, Biochemistry.

[7]  H. Stefánsson,et al.  Neuregulin 1 and susceptibility to schizophrenia. , 2002, American journal of human genetics.

[8]  G. Dayanithi,et al.  Ca2+‐regulated, neurosecretory granule channel involved in release from neurohypophysial terminals , 2002, The Journal of physiology.

[9]  R. Mrak,et al.  Nitric oxide synthase (NOS) in schizophrenia: increases in cerebellar vermis. , 1996, Molecular and chemical neuropathology.

[10]  M. Laruelle Imaging dopamine transmission in schizophrenia. A review and meta-analysis. , 1998, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[11]  D. Jeste,et al.  Hippocampal pathologic findings in schizophrenia. A morphometric study. , 1989, Archives of general psychiatry.

[12]  M. Webster,et al.  Application of cDNA microarrays to examine gene expression differences in schizophrenia , 2001, Brain Research Bulletin.

[13]  Dorit Ben-Shachar,et al.  Mitochondrial dysfunction in schizophrenia: a possible linkage to dopamine , 2002, Journal of neurochemistry.

[14]  J. Massagué TGF-beta signal transduction. , 1998, Annual review of biochemistry.

[15]  M. Lidow,et al.  Differential expression of D1 and D5 dopamine receptors in the fetal primate cerebral wall. , 1997, Cerebral cortex.

[16]  I. Batty,et al.  Muscarinic Receptors Mediate Phospholipase C-dependent Activation of Protein Kinase B via Ca2+, ErbB3, and Phosphoinositide 3-Kinase in 1321N1 Astrocytoma Cells* , 2002, The Journal of Biological Chemistry.

[17]  Hui Zhang,et al.  Oxidative stress increases internal calcium stores and reduces a key mitochondrial enzyme. , 2002, Biochimica et biophysica acta.

[18]  A. Pardee,et al.  Meeting report; “Molecular neurobiological mechanisms in schizophrenia: seeking a synthesis,” April 11–14, 1999 , 2000, Biological Psychiatry.

[19]  Angus C Nairn,et al.  The DARPP-32/protein phosphatase-1 cascade: a model for signal integration 1 Published on the World Wide Web on 22 January 1998. 1 , 1998, Brain Research Reviews.

[20]  Tsuyoshi Miyaoka,et al.  Increased expression of Wnt-1 in schizophrenic brains , 1999, Schizophrenia Research.

[21]  S. Muallem,et al.  G protein-dependent Ca2+ signaling complexes in polarized cells. , 1999, Cell calcium.

[22]  W H Wong,et al.  Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Deborah A Yurgelun-Todd,et al.  Differences in cerebellar blood volume in schizophrenia and bipolar disorder , 1999, Schizophrenia Research.

[24]  P. Goldman-Rakic,et al.  Long-Lasting Psychotomimetic Consequences of Repeated Low-Dose Amphetamine Exposure in Rhesus Monkeys , 1999, Neuropsychopharmacology.

[25]  E C Toescu,et al.  Apoptosis and cell death in neuronal cells: where does Ca2+ fit in? , 1998, Cell calcium.

[26]  L. Berrino,et al.  Effects of docosahexaenoic acid on calcium pathway in adult rat cardiomyocytes. , 2002, Life sciences.

[27]  N. Andreasen,et al.  Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-naïve patients , 1997, The Lancet.

[28]  F. Sharp,et al.  Phencyclidine induction of the hsp70 stress gene in injured pyramidal neurons is mediated via multiple receptors and voltage gated calcium channels , 1994, Neuroscience.

[29]  K. Blennow,et al.  Reduction of the small synaptic vesicle protein synaptophysin but not the large dense core chromogranins in the left thalamus of subjects with schizophrenia , 1999, Biological Psychiatry.

[30]  Pat Levitt,et al.  Molecular Characterization of Schizophrenia Viewed by Microarray Analysis of Gene Expression in Prefrontal Cortex , 2000, Neuron.

[31]  S. Fatemi,et al.  Altered levels of Reelin and its isoforms in schizophrenia and mood disorders , 2001, Neuroreport.

[32]  O. Shirakawa,et al.  Isotype-Specific G Protein Abnormalities in the Left Superior Temporal Cortex and Limbic Structures of Patients with Chronic Schizophrenia , 1998, Biological Psychiatry.

[33]  H. Lal,et al.  Oxidative stress and role of antioxidant and ω-3 essential fatty acid supplementation in schizophrenia , 2001, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[34]  P. Greengard,et al.  Synapsin I, an actin-binding protein regulating synaptic vesicle traffic in the nerve terminal. , 1994, Advances in second messenger and phosphoprotein research.

[35]  A. Guidotti,et al.  Dendritic Spine Hypoplasticity and Downregulation of Reelin and GABAergic Tone in Schizophrenia Vulnerability , 2001, Neurobiology of Disease.

[36]  G. Ramakers,et al.  N-methyl-d-aspartate-induced long-term depression is associated with a decrease in postsynaptic protein kinase C substrate phosphorylation in rat hippocampal slices , 2002, Neuroscience Letters.

[37]  K. Davis,et al.  Increased concentrations of presynaptic proteins in the cingulate cortex of subjects with schizophrenia. , 1997, Archives of general psychiatry.

[38]  B. Rudy,et al.  FGF-2 potentiates Ca(2+)-dependent inactivation of NMDA receptor currents in hippocampal neurons. , 1999, Journal of neurophysiology.

[39]  P G Nelson,et al.  Mechanisms involved in activity-dependent synapse formation in mammalian central nervous system cell cultures. , 1990, Journal of neurobiology.

[40]  D. Horrobin Schizophrenia as a membrane lipid disorder which is expressed throughout the body. , 1996, Prostaglandins, leukotrienes, and essential fatty acids.

[41]  F. Benes,et al.  A reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives , 1998, Biological Psychiatry.

[42]  F. Strumwasser,et al.  Antipsychotic drugs block IP3-dependent Ca2+-release from rat brain microsomes , 1996, Biological Psychiatry.

[43]  E. Yoon,et al.  Thrombin Receptors Activate Go Proteins in Endothelial Cells to Regulate Intracellular Calcium and Cell Shape Changes* , 2002, The Journal of Biological Chemistry.

[44]  T. Crow,et al.  G proteins (Gi, Go) in the medial temporal lobe in schizophrenia: preliminary report of a neurochemical correlate of structural change , 2005, Journal of Neural Transmission / General Section JNT.

[45]  D. Weinberger,et al.  Prefrontal function in schizophrenia: confounds and controversies. , 1996, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[46]  A. K. Lee,et al.  Dopamine (D2) receptor regulation of intracellular calcium and membrane capacitance changes in rat melanotrophs. , 1996, The Journal of physiology.

[47]  R. Hoffman,et al.  Schizophrenia as a disorder of developmentally reduced synaptic connectivity. , 2000, Archives of general psychiatry.

[48]  J. Olney,et al.  Glutamate receptor dysfunction and schizophrenia. , 1995, Archives of general psychiatry.

[49]  Tyrone D. Cannon,et al.  Neuropsychological functioning in siblings discordant for schizophrenia and healthy volunteers. , 1994, Archives of general psychiatry.

[50]  Paul J. Harrison The neuropathology of schizophrenia , 2008 .

[51]  D. Gerendasy,et al.  Homeostatic tuning of Ca2+ signal transduction by members of the calpacitin protein family , 1999, Journal of neuroscience research.

[52]  P. Greengard,et al.  Inhibition of Mitochondrial Complex II Induces a Long-Term Potentiation of NMDA-Mediated Synaptic Excitation in the Striatum Requiring Endogenous Dopamine , 2001, The Journal of Neuroscience.

[53]  J. Cadet,et al.  Free radical mechanisms in schizophrenia and tardive dyskinesia , 1994, Neuroscience & Biobehavioral Reviews.

[54]  B. Bunney,et al.  Pharmacological characterization of the receptor mediating electrophysiological responses to dopamine in the rat medial prefrontal cortex: a microiontophoretic study. , 1989, The Journal of pharmacology and experimental therapeutics.

[55]  F. Benes,et al.  Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. , 1991, Archives of general psychiatry.

[56]  Paul J. Harrison,et al.  Hippocampal and cortical growth-associated protein-43 messenger RNA in schizophrenia , 1998, Neuroscience.

[57]  F. Benes,et al.  Cellular colocalization of dopamine D1 and D2 receptors in rat medial prefrontal cortex , 1995, Synapse.

[58]  J. Palermo-neto Dopaminergic systems. Dopamine receptors. , 1997, The Psychiatric clinics of North America.

[59]  M. Lidow Neurotransmitter Receptors in Actions of Antipsychotic Medications , 2000 .

[60]  J. Bargas,et al.  D2 Dopamine Receptors in Striatal Medium Spiny Neurons Reduce L-Type Ca2+ Currents and Excitability via a Novel PLCβ1–IP3–Calcineurin-Signaling Cascade , 2000, The Journal of Neuroscience.

[61]  R. Shelton,et al.  A negative, double-blind, placebo-controlled, clinical trial of verapamil in chronic schizophrenia , 1986, Biological Psychiatry.

[62]  Aryeh Routtenberg,et al.  GAP-43: an intrinsic determinant of neuronal development and plasticity , 1997, Trends in Neurosciences.

[63]  J. Kornhuber,et al.  Iron, copper, zinc, magnesium, and calcium in postmortem brain tissue from schizophrenic patients , 1994, Biological Psychiatry.

[64]  P. Cohen,et al.  Mitogen-activated protein kinase kinase 7 is activated during low potassium-induced apoptosis in rat cerebellar granule neurons , 2002, Neuroscience Letters.

[65]  P. Goldman-Rakic,et al.  Up-regulation of neuronal calcium sensor-1 (NCS-1) in the prefrontal cortex of schizophrenic and bipolar patients , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[66]  J H Skene,et al.  GAP-43 as a 'calmodulin sponge' and some implications for calcium signalling in axon terminals. , 1990, Neuroscience research. Supplement : the official journal of the Japan Neuroscience Society.

[67]  C. Beasley,et al.  Neurochemical correlates of cortical GABAergic deficits in schizophrenia: selective losses of calcium binding protein immunoreactivity , 2001, Brain Research Bulletin.

[68]  J. Newcomer,et al.  NMDA receptor hypofunction model of schizophrenia. , 1999, Journal of psychiatric research.

[69]  F. Middleton,et al.  Gene Expression Profiling with DNA Microarrays: Advancing Our Understanding of Psychiatric Disorders , 2002, Neurochemical Research.

[70]  G. Johnson,et al.  Transient Increases in Intracellular Calcium Result in Prolonged Site-selective Increases in Tau Phosphorylation through a Glycogen Synthase Kinase 3β-dependent Pathway* , 1999, The Journal of Biological Chemistry.

[71]  S. Chan,et al.  Human brain contents of calcium, copper, magnesium, and zinc in some neurological pathologies. , 1975, Clinica chimica acta; international journal of clinical chemistry.

[72]  W. Leonhardt,et al.  Antioxidative action of the novel calcium channel antagonist mibefradil on low-density lipoproteins , 1998, European Journal of Clinical Pharmacology.

[73]  P. Goldman-Rakic Working memory dysfunction in schizophrenia. , 1994, The Journal of neuropsychiatry and clinical neurosciences.

[74]  C. Bramham,et al.  Modulation of neuronal calcium signaling by neurotrophic factors , 2002, International Journal of Developmental Neuroscience.

[75]  F. Di Virgilio,et al.  A role for calcium in Bcl-2 action? , 2002, Biochimie.

[76]  D. Souza,et al.  Increased serum S100B protein in schizophrenia: a study in medication-free patients. , 2001, Journal of psychiatric research.

[77]  R. Segal,et al.  Sustained Signaling by Phospholipase C-γ Mediates Nerve Growth Factor-Triggered Gene Expression , 2001, Molecular and Cellular Biology.

[78]  J John Mann,et al.  The GABAergic system in schizophrenia. , 2002, The international journal of neuropsychopharmacology.

[79]  R. D. Schwartz,et al.  Bidirectional Modulation of GABA‐Gated Chloride Channels by Divalent Cations: Inhibition by Ca2+ and Enhancement by Mg2+ , 1994, Journal of neurochemistry.

[80]  M. Mattson,et al.  NT-3 and BDNF protect CNS neurons against metabolic/excitotoxic insults , 1994, Brain Research.

[81]  P. Seeman,et al.  Schizophrenia: elevated mRNA for calcium-calmodulin-dependent protein kinase IIbeta in frontal cortex. , 2000, Brain research. Molecular brain research.

[82]  S. Kish,et al.  Differential alteration of phospholipase A2 activities in brain of patients with schizophrenia , 1999, Brain Research.

[83]  N. Perrone-Bizzozero,et al.  Posttranscriptional regulation of GAP-43 gene expression in PC12 cells through protein kinase C-dependent stabilization of the mRNA , 1993, The Journal of cell biology.

[84]  E. G. Jones,et al.  Maldistribution of interstitial neurons in prefrontal white matter of the brains of schizophrenic patients. , 1996, Archives of general psychiatry.

[85]  K. Sato,et al.  Effect of haloperidol on cyclic AMP and inositol trisphosphate in rat striatum in vivo. , 1992, Prostaglandins, leukotrienes, and essential fatty acids.

[86]  G. Bellomo,et al.  Oxidative stress injury studied in isolated intact cells. , 1987, Molecular toxicology.

[87]  G. Westbrook,et al.  Interactions of Calmodulin and α-Actinin with the NR1 Subunit Modulate Ca2+-Dependent Inactivation of NMDA Receptors , 1999, The Journal of Neuroscience.

[88]  Robert Zöchling,et al.  Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses , 2001, Schizophrenia Research.

[89]  M. Isokawa Modulation of GABAA receptor-mediated inhibition by postsynaptic calcium in epileptic hippocampal neurons , 1998, Brain Research.

[90]  H. Möller,et al.  Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophrenia , 2001, Schizophrenia Research.

[91]  P. Goldman-Rakic,et al.  Presynaptic regulation of recurrent excitation by D1 receptors in prefrontal circuits. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[92]  Jun Wang,et al.  Acceleration of trophoblast differentiation by heparin-binding EGF-like growth factor is dependent on the stage-specific activation of calcium influx by ErbB receptors in developing mouse blastocysts. , 2000, Development.

[93]  C. Bruehl,et al.  Polyunsaturated fatty acids modulate sodium and calcium currents in CA1 neurons. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[94]  Gary Fiskum,et al.  Regulation of hydrogen peroxide production by brain mitochondria by calcium and Bax , 2002, Journal of neurochemistry.

[95]  W. Weglicki,et al.  Protective effects of dihydropyridine Ca-blockers against endothelial cell oxidative injury due to combined nitric oxide and superoxide. , 2002, Pharmacological research.

[96]  N. Popov,et al.  Influence of dopamine receptor agonists and antagonists on calmodulin translocation in different brain regions. , 1989, European journal of pharmacology.

[97]  J. Benjamins,et al.  Increased intracellular calcium alters myelin gene expression in the N20.1 oligodendroglial cell line , 1999, Journal of neuroscience research.

[98]  I. Gottesman,et al.  The glial growth factors deficiency and synaptic destabilization hypothesis of schizophrenia , 2002, BMC psychiatry.

[99]  H. Vaudry,et al.  Effect of dopamine on adenylate cyclase activity, polyphosphoinositide metabolism and cytosolic calcium concentrations in frog pituitary melanotrophs. , 1993, The Journal of endocrinology.

[100]  A. Tort,et al.  Decreased S100-beta protein in schizophrenia: preliminary evidence , 2000, Schizophrenia Research.

[101]  S. Hirsch,et al.  Elevated platelet calcium mobilization and nitric oxide synthase activity may reflect abnormalities in schizophrenic brain. , 1995, Biochemical and biophysical research communications.

[102]  Mark P. Mattson,et al.  Calcium as sculptor and destroyer of neural circuitry , 1992, Experimental Gerontology.

[103]  D. Weinberger,et al.  The effect of apomorphine on regional cerebral blood flow in schizophrenia. , 1989, The Journal of neuropsychiatry and clinical neurosciences.

[104]  Paul J. Harrison,et al.  Synaptophysin gene expression in schizophrenia , 2000, British Journal of Psychiatry.

[105]  Katsuhiko Mikoshiba,et al.  The Wnt/calcium pathway activates NF-AT and promotes ventral cell fate in Xenopus embryos , 2002, Nature.

[106]  C. Heizmann,et al.  S100 proteins: structure, functions and pathology. , 2002, Frontiers in bioscience : a journal and virtual library.

[107]  E. Warburton,et al.  Calcium dependence of sensitised dopamine release in rat nucleus accumbens following amphetamine challenge: implications for the disruption of latent inhibition , 1996, Behavioural pharmacology.

[108]  J. Satrústegui,et al.  Effects of chronic nimodipine on working memory of old rats in relation to defects in synaptosomal calcium homeostasis. , 1998, European journal of pharmacology.

[109]  A. Yarlagadda Role of calcium regulation in pathophysiology model of schizophrenia and possible interventions. , 2002, Medical hypotheses.

[110]  C. Bergson,et al.  D1/D5 dopamine receptors stimulate intracellular calcium release in primary cultures of neocortical and hippocampal neurons. , 2002, Journal of neurophysiology.

[111]  Daniel R Weinberger,et al.  Microarray analysis of gene expression in the prefrontal cortex in schizophrenia: a preliminary study , 2002, Schizophrenia Research.

[112]  Fabio Benfenati,et al.  Synaptic vesicle-associated Ca2+/calmodulin-dependent protein kinase II is a binding protein for synapsin I , 1992, Nature.

[113]  P. Gonçalves,et al.  Ca2+ Sensitivity of Synaptic Vesicle Dopamine, γ-Aminobutyric Acid, and Glutamate Transport Systems , 2004, Neurochemical Research.

[114]  Shaoyu Zhou,et al.  Interference with calcium-dependent mitochondrial bioenergetics in cardiac myocytes isolated from doxorubicin-treated rats. , 2001, Toxicology and applied pharmacology.

[115]  J. Lehmann,et al.  Functional Screening of G Protein—Coupled Receptors by Measuring Intracellular Calcium with a Fluorescence Microplate Reader , 2002, Journal of biomolecular screening.

[116]  G. Rosenbaum,et al.  Comparison of sernyl with other drugs: simulation of schizophrenic performance with sernyl, LSD-25, and amobarbital (amytal) sodium; I. Attention, motor function, and proprioception. , 1959, A.M.A. archives of general psychiatry.

[117]  F. Benes,et al.  Quantitative cytoarchitectural studies of the cerebral cortex of schizophrenics. , 1986, Archives of general psychiatry.

[118]  B. Bogerts,et al.  Cell loss in the hippocampus of schizophrenics , 2004, European archives of psychiatry and neurological sciences.

[119]  P. Goldman-Rakic,et al.  Dopamine D2 and D3 receptors are linked to the actin cytoskeleton via interaction with filamin A , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[120]  D. Copolov,et al.  Biological markers and schizophrenia. , 2000, The Australian and New Zealand journal of psychiatry.

[121]  M. Berk,et al.  The platelet as a peripheral marker in psychiatric illness , 2001, Human psychopharmacology.

[122]  A. Schousboe,et al.  Role of GABAB receptors in intracellular Ca2+ homeostasis and possible interaction between GABAA and GABAB receptors in regulation of transmitter release in cerebellar granule neurons , 1994, Journal of neuroscience research.

[123]  Helen L. Yin,et al.  Gelsolin, a Multifunctional Actin Regulatory Protein* , 1999, The Journal of Biological Chemistry.

[124]  J. Coyle,et al.  Glutamatergic mechanisms in schizophrenia. , 2003, Annual review of pharmacology and toxicology.

[125]  Yogesh K. Dwivedi,et al.  A decrease of reelin expression as a putative vulnerability factor in schizophrenia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[126]  O. Shirakawa,et al.  Opposite changes in phosphoinositide-specific phospholipase C immunoreactivity in the left prefrontal and superior temporal cortex of patients with chronic schizophrenia , 1999, Biological Psychiatry.

[127]  M. Valdeolmillos,et al.  Receptor-activated calcium signals in tangentially migrating cortical cells. , 2002, Cerebral cortex.

[128]  L. Pallanck,et al.  NSF Function in Neurotransmitter Release Involves Rearrangement of the SNARE Complex Downstream of Synaptic Vesicle Docking , 1998, The Journal of Neuroscience.

[129]  Douglas W. Jones,et al.  The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[130]  C. Beasley,et al.  Glycogen synthase kinase-3β immunoreactivity is reduced in the prefrontal cortex in schizophrenia , 2001, Neuroscience Letters.

[131]  Yu Tian Wang,et al.  Dual Regulation of NMDA Receptor Functions by Direct Protein-Protein Interactions with the Dopamine D1 Receptor , 2002, Cell.

[132]  W. Fenton,et al.  Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia , 2000, Biological Psychiatry.

[133]  T. Goldberg,et al.  Cognitive impairment in schizophrenia is the core of the disorder. , 2000, Critical reviews in neurobiology.

[134]  C. Pantelis,et al.  Implications of Lipid Biology for the Pathogenesis of Schizophrenia , 2002, The Australian and New Zealand journal of psychiatry.

[135]  R. Levenson,et al.  D2 and D3 dopamine receptor cell surface localization mediated by interaction with protein 4.1N. , 2002, Molecular pharmacology.

[136]  J. Kaplan,et al.  CaMKII regulates the density of central glutamatergic synapses in vivo , 1999, Nature.

[137]  Jeffrey K. Yao,et al.  Oxidative Damage and Schizophrenia , 2001, CNS drugs.

[138]  C. Iadecola,et al.  Regulation of the cerebral microcirculation during neural activity: is nitric oxide the missing link? , 1993, Trends in Neurosciences.

[139]  A. Strunecká,et al.  What can the investigation of phosphoinositide signaling system in platelets of schizophrenic patients tell us? , 1999, Prostaglandins, leukotrienes, and essential fatty acids.

[140]  G. Krauss Biochemistry of signal transduction and regulation , 1999 .

[141]  C. Guerri,et al.  Astrocytes in culture express the full-length Trk-B receptor and respond to brain derived neurotrophic factor by changing intracellular calcium levels: effect of ethanol exposure in rats , 2000, Neuroscience Letters.

[142]  W. Honer,et al.  Synaptic and plasticity-associated proteins in anterior frontal cortex in severe mental illness , 1999, Neuroscience.

[143]  D. Lewis,et al.  Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia , 2001, Molecular Psychiatry.

[144]  M. Webster,et al.  Multivariate analysis of prefrontal cortical data from the Stanley Foundation Neuropathology Consortium , 2001, Brain Research Bulletin.

[145]  M. Wiesmann,et al.  Elevated plasma levels of S-100b protein in schizophrenic patients , 1999, Biological Psychiatry.

[146]  Ramin Homayouni,et al.  Reelin Is a Ligand for Lipoprotein Receptors , 1999, Neuron.

[147]  H Y Wang,et al.  Evidence for the coupling of Gq protein to D1-like dopamine sites in rat striatum: possible role in dopamine-mediated inositol phosphate formation. , 1995, Molecular pharmacology.

[148]  F. Angelucci,et al.  Data and hypotheses on the role of nerve growth factor and other neurotrophins in psychiatric disorders. , 2000, Medical hypotheses.

[149]  A. Arnsten,et al.  D1 dopamine receptors in the mouse prefrontal cortex: Immunocytochemical and cognitive neuropharmacological analyses , 2003, Synapse.

[150]  E. Gundelfinger,et al.  Intracellular neuronal calcium sensor proteins: a family of EF-hand calcium-binding proteins in search of a function , 1999, Cell and Tissue Research.

[151]  Chau-Chung Wu,et al.  Arachidonic acid‐induced H+ and Ca2+ increases in both the cytoplasm and nucleoplasm of rat cerebellar granule cells , 2001, The Journal of physiology.

[152]  P. Goldman-Rakic,et al.  Dual signaling regulated by calcyon, a D1 dopamine receptor interacting protein. , 2000, Science.

[153]  H Nawa,et al.  Cytokine and growth factor involvement in schizophrenia—support for the developmental model , 2000, Molecular Psychiatry.

[154]  K. Davies,et al.  Calcium and oxidative stress: from cell signaling to cell death. , 2002, Molecular immunology.

[155]  T. Sawada,et al.  Inhibiting neuronal migration by blocking NMDA receptors in the embryonic rat cerebral cortex: a tissue culture study. , 1999, Brain research. Developmental brain research.

[156]  P. Goldman-Rakic,et al.  The cerebral cortex: a case for a common site of action of antipsychotics. , 1998, Trends in pharmacological sciences.

[157]  D. Swanson,et al.  Calcium-independent phospholipase A2 and schizophrenia. , 1998, Archives of general psychiatry.

[158]  Jeffrey C. Erlich,et al.  Increased phospholipid breakdown in schizophrenia. Evidence for the involvement of a calcium-independent phospholipase A2. , 1997, Archives of general psychiatry.

[159]  V. Tkachuk,et al.  Heterotrimeric Gi protein is associated with the inositol 1,4,5-trisphosphate receptor complex and modulates calcium flux. , 1998, Cell calcium.

[160]  M. Lidow General Overview of Contemporary Antipsychotic Medications , 2000 .

[161]  R. McCarron,et al.  Dopaminergic Receptors Linked to Adenylate Cyclase in Human Cerebromicrovascular Endothelium , 1991, Journal of neurochemistry.

[162]  P. Goldman-Rakic,et al.  Up-regulation of the D1 dopamine receptor-interacting protein, calcyon, in patients with schizophrenia. , 2003, Archives of general psychiatry.

[163]  S. Arnold,et al.  Neurodevelopmental abnormalities in schizophrenia: Insights from neuropathology , 1999, Development and Psychopathology.

[164]  Anirvan Ghosh,et al.  Calcium Regulation of Dendritic Growth via CaM Kinase IV and CREB-Mediated Transcription , 2002, Neuron.

[165]  P. Goldman-Rakic,et al.  Interaction with Neuronal Calcium Sensor NCS-1 Mediates Desensitization of the D2 Dopamine Receptor , 2002, The Journal of Neuroscience.

[166]  J. R. Möller Rapid conversion of myelin-associated glycoprotein to a soluble derivative in primates , 1996, Brain Research.

[167]  F. Benes,et al.  GABAergic Interneurons: Implications for Understanding Schizophrenia and Bipolar Disorder , 2001, Neuropsychopharmacology.

[168]  A Carlsson,et al.  Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. , 2001, Annual review of pharmacology and toxicology.

[169]  N. Brandon,et al.  GABAA Receptor Phosphorylation and Functional Modulation in Cortical Neurons by a Protein Kinase C-dependent Pathway* , 2000, The Journal of Biological Chemistry.

[170]  S. Cragg,et al.  Dopamine receptors--physiological understanding to therapeutic intervention potential. , 1999, Pharmacology & therapeutics.

[171]  E. I. Astashkin,et al.  A dual effect of arachidonic acid on Ca2+ transport systems in lymphocytes , 1994, FEBS letters.

[172]  T. Crow,et al.  Reduced concentrations of the α-subunit of GTP-binding protein Go in schizophrenic brain , 2005, Journal of Neural Transmission / General Section JNT.

[173]  H. Ahorn,et al.  Binding of Calmodulin to the D2-Dopamine Receptor Reduces Receptor Signaling by Arresting the G Protein Activation Switch* , 2000, The Journal of Biological Chemistry.

[174]  J. Yesavage,et al.  Acute phencyclidine (PCP) intoxication: psychopathology and prognosis. , 1978, The Journal of clinical psychiatry.

[175]  F. Goodwin,et al.  CSF calcium: clinical correlates in affective illness and schizophrenia. , 1979, Biological psychiatry.

[176]  J. Mazière,et al.  Could the interaction of neuroleptics with calmodulin be an "explanation" of the psychotropic effects? , 1991, L'Encephale.

[177]  J. Kleinman,et al.  Synaptophysin and GAP-43 mRNA levels in the hippocampus of subjects with schizophrenia , 2001, Schizophrenia Research.

[178]  C. Casagrande,et al.  Peripheral vascular and neuronal effects of dopamine receptor agonists. A comparison with receptor binding studies in rat striatum , 1990, Naunyn-Schmiedeberg's Archives of Pharmacology.

[179]  Guoqiang Xing,et al.  Decreased calcium-dependent constitutive nitric oxide synthase (cNOS) activity in prefrontal cortex in schizophrenia and depression , 2002, Schizophrenia Research.

[180]  B. Bogerts,et al.  Increased number of nitric oxide synthase immunoreactive Purkinje cells and dentate nucleus neurons in schizophrenia , 2001, Journal of neurocytology.

[181]  P. Goldman-Rakic,et al.  Modulation of memory fields by dopamine Dl receptors in prefrontal cortex , 1995, Nature.

[182]  R. Donato,et al.  S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. , 2001, The international journal of biochemistry & cell biology.

[183]  P. Sastry,et al.  Apoptosis and the Nervous System , 2000, Journal of neurochemistry.

[184]  K. Blennow,et al.  Mitochondrial Function is Differentially Altered in the Basal Ganglia of Chronic Schizophrenics , 1999, Neuropsychopharmacology.

[185]  C. Kahn,et al.  Frataxin activates mitochondrial energy conversion and oxidative phosphorylation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[186]  N. Perrone-Bizzozero,et al.  Levels of the growth-associated protein GAP-43 are selectively increased in association cortices in schizophrenia. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[187]  D. Goff,et al.  Glutamate in schizophrenia: clinical and research implications , 1997, Schizophrenia Research.

[188]  Paul Greengard,et al.  Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia. , 2002, Archives of general psychiatry.

[189]  S. Muallem,et al.  RGS Proteins Determine Signaling Specificity of Gq-coupled Receptors* , 1999, The Journal of Biological Chemistry.

[190]  P. Greengard,et al.  A Dopamine/D1 Receptor/Protein Kinase A/Dopamine- and cAMP-Regulated Phosphoprotein (Mr 32 kDa)/Protein Phosphatase-1 Pathway Regulates Dephosphorylation of the NMDA Receptor , 1998, The Journal of Neuroscience.

[191]  William Byne,et al.  Evidence for a decrease in basilar dendrites of pyramidal cells in schizophrenic medial prefrontal cortex , 2002, Schizophrenia Research.

[192]  P. Goldman-Rakic,et al.  The reduced neuropil hypothesis: a circuit based model of schizophrenia , 1999, Biological Psychiatry.

[193]  C. Tanaka,et al.  D2‐dopamine receptor‐mediated inhibition of intracellular Ca2+ mobilization and release of acetylcholine from guinea‐pig neostriatal slices , 1987, British Journal of Pharmacology.

[194]  D. Javitt,et al.  Recent advances in the phencyclidine model of schizophrenia. , 1991, The American journal of psychiatry.

[195]  H. Nawa,et al.  Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients , 2002, Psychiatry Research.

[196]  A. Meyer-Lindenberg,et al.  Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia , 2002, Nature Neuroscience.

[197]  A. Martínez-Serrano,et al.  Modulation of presynaptic calcium homeostasis by nitric oxide. , 1996, Cell calcium.

[198]  Akira Sawa,et al.  Schizophrenia: Diverse Approaches to a Complex Disease , 2002, Science.

[199]  J. Pierri,et al.  Gene Expression Profiling Reveals Alterations of Specific Metabolic Pathways in Schizophrenia , 2002, The Journal of Neuroscience.

[200]  J. Glowinski,et al.  Variation in the ability of neuroleptics to block the inhibitory influence of dopaminergic neurons on the activity of cells in the rat prefrontal cortex , 1986, Brain Research Bulletin.

[201]  C. Gerfen The neostriatal mosaic: multiple levels of compartmental organization. , 1992 .

[202]  C. Davio,et al.  Molecular mechanisms involved in the actions of apotransferrin upon the central nervous system: Role of the cytoskeleton and of second messengers , 2002, Journal of neuroscience research.

[203]  B. Dean,et al.  Changes in protein kinase C and adenylate cyclase in the temporal lobe from subjects with schizophrenia , 2005, Journal of Neural Transmission.

[204]  J. Lieberman,et al.  Cortical Bcl-2 protein expression and apoptotic regulation in schizophrenia , 2000, Biological Psychiatry.

[205]  B. Bogerts,et al.  Hippocampal expression of the calcium sensor protein visinin-like protein-1 in schizophrenia , 2002, Neuroreport.

[206]  G J Barker,et al.  In vivo investigation of white matter pathology in schizophrenia with magnetisation transfer imaging , 2000, Journal of neurology, neurosurgery, and psychiatry.

[207]  N. Perrone-Bizzozero,et al.  Increased levels of GAP-43 protein in schizophrenic brain tissues demonstrated by a novel immunodetection method. , 1995, Molecular and chemical neuropathology.

[208]  George Bartzokis,et al.  Schizophrenia: Breakdown in the Well-regulated Lifelong Process of Brain Development and Maturation , 2002, Neuropsychopharmacology.

[209]  G. Westbrook,et al.  Calcineurin acts via the C-terminus of NR2A to modulate desensitization of NMDA receptors , 2002, Neuropharmacology.

[210]  T. Taguchi,et al.  Basic Fibroblast Growth Factor Evokes a Rapid Glutamate Release through Activation of the MAPK Pathway in Cultured Cortical Neurons* , 2002, The Journal of Biological Chemistry.

[211]  R. Moon,et al.  The Wnt/Ca2+ pathway: a new vertebrate Wnt signaling pathway takes shape. , 2000, Trends in genetics : TIG.

[212]  M. Segal Rapid plasticity of dendritic spine: hints to possible functions? , 2001, Progress in Neurobiology.

[213]  M. Ishii,et al.  Ca2+ Elevation Evoked by Membrane Depolarization Regulates G Protein Cycle via RGS Proteins in the Heart , 2001, Circulation research.

[214]  M. Owen,et al.  Dopamine receptors and schizophrenia: contribution of molecular genetics and clinical neuropsychology. , 1999, The international journal of neuropsychopharmacology.

[215]  E. F. Stanley,et al.  G-Protein Types Involved in Calcium Channel Inhibition at a Presynaptic Nerve Terminal , 2000, The Journal of Neuroscience.

[216]  M. Gnegy,et al.  Enhanced Amphetamine- and K+-Mediated Dopamine Release in Rat Striatum after Repeated Amphetamine: Differential Requirements for Ca2+- and Calmodulin-Dependent Phosphorylation and Synaptic Vesicles , 1999, The Journal of Neuroscience.

[217]  N. Spitzer,et al.  Regulation of Calcineurin by Growth Cone Calcium Waves Controls Neurite Extension , 2000, The Journal of Neuroscience.

[218]  V. Němcová,et al.  Phospholipids and calcium alterations in platelets of schizophrenic patients. , 1997, Physiological research.

[219]  A. van Ooyen,et al.  The role of calcium signaling in early axonal and dendritic morphogenesis of rat cerebral cortex neurons under non-stimulated growth conditions. , 2001, Brain research. Developmental brain research.

[220]  G. Reynolds,et al.  Neuronal calcium-binding proteins and schizophrenia , 2002, Schizophrenia Research.

[221]  M. Gnegy,et al.  Repeated haloperidol increases both calmodulin and a calmodulin-binding protein in rat striatum. , 1994, Brain research. Molecular brain research.

[222]  E. Friedman,et al.  Stimulation of a dopamine D1 receptor enhances inositol phosphates formation in rat brain. , 1990, The Journal of pharmacology and experimental therapeutics.

[223]  K. Blennow,et al.  Putamen Mitochondrial Energy Metabolism Is Highly Correlated to Emotional and Intellectual Impairment in Schizophrenics , 2000, Neuropsychopharmacology.

[224]  Stephan Heckers,et al.  Schizophrenia and cognitive function , 2000, Current Opinion in Neurobiology.

[225]  B. Orser,et al.  A D2 Class Dopamine Receptor Transactivates a Receptor Tyrosine Kinase to Inhibit NMDA Receptor Transmission , 2002, Neuron.

[226]  B. Ross,et al.  Clinical subtyping reveals significant differences in calcium-dependent phospholipase A2 activity in schizophrenia , 1999, Biological Psychiatry.

[227]  J. Seamans,et al.  Developing a Neuronal Model for the Pathophysiology of Schizophrenia Based on the Nature of Electrophysiological Actions of Dopamine in the Prefrontal Cortex , 1999, Neuropsychopharmacology.

[228]  R. Belmaker,et al.  GSK-3 and the neurodevelopmental hypothesis of schizophrenia , 2002, European Neuropsychopharmacology.

[229]  H. Kaiya Second messenger imbalance hypothesis of schizophrenia. , 1992 .

[230]  J. Kleinman,et al.  Reduced GAP-43 mRNA in dorsolateral prefrontal cortex of patients with schizophrenia. , 2001, Cerebral cortex.

[231]  E G Jones,et al.  Subnucleus-specific loss of neurons in medial thalamus of schizophrenics. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[232]  K. Blennow,et al.  Reduction of the synaptophysin level but normal levels of glycerophospholipids in the gyrus cinguli in schizophrenia , 2002, Schizophrenia Research.

[233]  G. Sobal,et al.  Calcium antagonists as inhibitors of in vitro low density lipoprotein oxidation and glycation. , 2001, Biochemical pharmacology.

[234]  Y. Mori,et al.  Binding of Gαo N Terminus Is Responsible for the Voltage-resistant Inhibition of α1A (P/Q-type, Cav2.1) Ca2+ Channels* , 2001, The Journal of Biological Chemistry.

[235]  B. Weiss,et al.  Interaction of drugs with calmodulin. Biochemical, pharmacological and clinical implications. , 1982, Biochemical pharmacology.

[236]  R. Freedman,et al.  Significant reductions in synapsin but not synaptophysin specific activity in the brains of some schizophrenics , 1993, Biological Psychiatry.